Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
10.63
+0.03 (0.28%)
At close: Jun 18, 2025, 4:00 PM
10.62
-0.01 (-0.09%)
After-hours: Jun 18, 2025, 4:04 PM EDT

Theravance Biopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
5314635607558141,137
Upgrade
Market Cap Growth
2.25%-17.33%-25.82%-7.35%-28.37%-22.63%
Upgrade
Enterprise Value
4484164773201,2691,398
Upgrade
Last Close Price
10.629.4111.2411.2211.0517.77
Upgrade
PE Ratio
---0.87--
Upgrade
PS Ratio
8.017.199.7514.7014.7215.82
Upgrade
PB Ratio
3.202.642.631.71-2.40-3.74
Upgrade
P/TBV Ratio
3.202.642.631.71--
Upgrade
EV/Sales Ratio
6.876.478.306.2322.9519.46
Upgrade
Debt / Equity Ratio
0.290.280.230.12-1.98-2.23
Upgrade
Asset Turnover
0.180.180.120.110.130.16
Upgrade
Quick Ratio
4.644.894.8411.993.202.93
Upgrade
Current Ratio
4.775.025.3912.314.263.18
Upgrade
Return on Equity (ROE)
-31.46%-29.04%-16.86%-179.84%--
Upgrade
Return on Assets (ROA)
-7.98%-7.21%-6.78%-10.07%-35.20%-42.38%
Upgrade
Return on Capital (ROIC)
-12.22%-10.88%-8.87%-11.99%-42.23%-56.44%
Upgrade
Earnings Yield
-10.99%-12.19%-9.86%115.58%-24.49%-24.45%
Upgrade
FCF Yield
6.08%-2.56%-5.27%-24.86%-25.94%-22.61%
Upgrade
Buyback Yield / Dilution
4.72%11.67%24.85%-5.95%-11.41%-12.11%
Upgrade
Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q